TMS Maine provides Transcranial Magnetic Stimulation therapy for treatment-resistant depression, conveniently located in South Portland, Maine and servicing all of Northern New England.
Edward J. Bilotti, M.D.
Dr. Bilotti has over 20 years of practice
experience. He specializes in treating
patients with mental health disorders
and addictions. His particular clinical
interests are in medication-assisted
treatment of opiate use disorders,
co-occurring disorders, and affective
disorders. Dr. Bilotti is Clinical Asst.
Professor at Tufts University School of
Medicine. He is Board-Certified by the American Board
of Psychiatry and Neurology, a Fellow of the American Psychiatric Association, and is also Board Certified in Addiction Medicine.
Dr. Bilotti is a graduate of Tufts Medical School. He completed residency training in psychiatry at Robert Wood Johnson University Hospital. In 1999, he launched Aroga Behavioral Health of Princeton (Aroga), which grew to become a multi-site, interdisciplinary group practice serving more than 3,000 patients. He was one of the first to obtain a waiver and begin treating opiate use disorder patients with Suboxone, developing several opiate treatment programs within Aroga. In 2009, Dr. Bilotti founded the TMS Center of Princeton, becoming the first in New Jersey, and one of the first in the United States, to provide transcranial magnetic stimulation (TMS) as a therapy for treatment-resistant depression.
In 2012, Dr. Bilotti left Aroga and the TMS Center of Princeton to relocate to Maine, his favorite place to vacation for many years. In Maine, Dr. Bilotti has served as the Medical Director of the Partial Hospital and Dual Diagnosis Intensive Outpatient programs at Maine Medical Center, Medical Director of Mercy Recovery Center. and, most recently, Medical Director of Psychiatric Services at Southern Maine Healthcare, where he oversaw clinical services for inpatient, consultation-liaison, psychiatric emergency department, and partial hospital/intensive outpatient programs.
Peter Mirkin, M.D.
Dr. Peter Mirkin has been practicing
psychiatry for over 40 years, providing
treatment for patients with mental health
problems and addictions.
He is a consultant and affiliated provider
at Spurwink Adult Behavioral
Health in Portland, is the Medical
Director of Oxford County Mental Health
Services, is on the staff of Maine Health and is a Clinical Assistant
Professor at Tufts University School of Medicine. He is Board Certified by the American Board of Psychiatry and Neurology, and licensed to prescribe Buprenorphine. He is a Life Member of the American Psychiatric Association and a Fellow of the American College of Medical Quality.
Dr. Mirkin graduated from the University of Cape Town Medical School.
Following psychiatric residencies in Cape Town and London, he completed an additional residency at the University of Connecticut Medical Center as well as a fellowship there in Alcohol Use Disorders at the NIMH funded Center for the Study of Alcoholism.
He subsequently served as the Director of Inpatient Psychiatry and
Assistant Director of the Psychiatry Department of Hartford Hospital in Connecticut. During that time, he completed an MBA at Rensselaer Polytechnic Institute.
After vacationing for some years in Maine, Dr. Mirkin moved here from Connecticut in 1996 with his family and has provided psychiatric services at Maine Medical Center, Counseling Services, Inc., Southern Maine Healthcare, Oxford County Mental Health Services and Spurwink Adult Behavioral Health Services. During this time he has also taught Tufts Medical students in a program designed to bring doctors-in-training to rural Maine.
As a part of his focus on managing treatment-resistant depression, Dr. Mirkin developed an interest in Transcranial Magnetic Stimulation and in 2011 completed a training program at the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center, Harvard Medical School.
Dr. Mirkin has collaborated with Dr. Edward J. Bilotti to establish TMS of Maine to provide Maine patients with expanded treatment options.